🇪🇺 Fecal Microbial Transplantation by capsules in European Union

EMA authorised Fecal Microbial Transplantation by capsules on 20 July 2015

Marketing authorisation

EMA — authorised 20 July 2015

• Application: EMEA/H/C/003840
• Marketing authorisation holder: Bristol-Myers Squibb Pharma EEIG
• Local brand name: Nivolumab BMS
• Indication: Nivolumab BMS is indicated for the treatment of locally advanced or metastatic squamous non-small cell lung cancer (NSCLC) after prior chemotherapy in adults.
• Status: withdrawn

Read official source →

Frequently asked questions

Is Fecal Microbial Transplantation by capsules approved in European Union?

Yes. EMA authorised it on 20 July 2015.

Who is the marketing authorisation holder for Fecal Microbial Transplantation by capsules in European Union?

Bristol-Myers Squibb Pharma EEIG holds the EU marketing authorisation.